Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

REGENXBIO Inc. - Common Stock (NQ:RGNX)

11.98 +0.15 (+1.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about REGENXBIO Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
What's Going On With REGENXBIO Shares Monday? ↗
REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy. 
Via Benzinga
News headline image
Twist Bioscience Posts Upbeat Results, Joins Tesla, Amylyx Pharmaceuticals, Regenxbio And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
5 Analysts Have This To Say About Regenxbio ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
What 4 Analyst Ratings Have To Say About Regenxbio ↗
 
Via Benzinga
News headline image
Assessing Regenxbio: Insights From 5 Financial Analysts ↗
 
Via Benzinga
News headline image
Where Regenxbio Stands With Analysts ↗
 
Via Benzinga
News headline image
Assessing Regenxbio: Insights From 4 Financial Analysts ↗
 
Via Benzinga
News headline image
Evaluating Regenxbio: Insights From 9 Financial Analysts ↗
 
Via Benzinga
News headline image
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
7 Biotech Stocks to Buy for Their Game-Changing Potential ↗
Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. 
Via InvestorPlace
News headline image
Why Is Clearside Biomedical Stock Gaining Today? ↗
Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS... 
Via Benzinga
News headline image
7 Biotech Stocks to Buy on the Dip: June 2024 ↗
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
News headline image
Where Regenxbio Stands With Analysts ↗
 
Via Benzinga
News headline image
Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock ↗
 
Via Benzinga
News headline image
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
News headline image
FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy ↗
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older with specific DMD gene mutations. 
Via Benzinga
News headline image
Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy ↗
The agency signed off on Elevidys for a broad population of children with the muscle-wasting disease. 
Via Investor's Business Daily
News headline image
Regenxbio: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Earnings Scheduled For February 27, 2024 ↗
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million. 
Via Benzinga
News headline image
Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test ↗
Sarepta is now just awaiting the FDA's decision on whether to fully approve its gene therapy, and for whom. 
Via Investor's Business Daily
News headline image
Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside ↗
Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform. 
Via Benzinga
News headline image
RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024 ↗
RGNX stock results show that Regenxbio missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? ↗
The threat is still emerging, but it could be significant. 
Via The Motley Fool
News headline image
This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO ↗
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 trial results in Duchenne patients. 
Via Benzinga
News headline image
REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars ↗
Latest updates on safety and efficacy in the Phase 1/2 AFFINITY DUCHENNE trial for Duchenne muscular dystrophy. Positive results, no serious adverse events. Expect pivotal dose determination by... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. 
Via Benzinga
Topics Stocks
News headline image
Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of Zscaler, Inc. (NASDAQ: ZS) shares fell sharply during Friday’s session following second-quarter results. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.